Literature DB >> 28848134

Selection of Surgical Methods in the Treatment of Upper Tibia Osteosarcoma and Prognostic Analysis.

Ya Zhang, Zeiwei He, Yi Li, Yihao Yang, Jiandang Shi, Xuefeng Liu, Tao Yuan, Junfeng Xia, Dongqi Li, Jing Zhang, Zuozhang Yang.   

Abstract

BACKGROUND: We aimed to explore the clinical effects and prognosis of different surgical methods in upper tibia osteosarcoma.
METHODS: Among 112 patients with proximal upper tibia osteosarcoma, 40 patients were treated with amputation, 20 patients were treated with massive osteoarticular allograft, and the remaining 52 cases were treated with tumor resection and artificial joint replacement.
RESULTS: Recurrence was observed in 2 cases (5%) in the amputation group, in 6 cases (30%) in the massive osteoarticular allograft group, and in 6 cases (12%) in the tumor resection and artificial joint replacement group (P = 0.021). The lung metastasis rates were 40% in the amputation group, 40% in the massive osteoarticular allograft group, and 38% in the tumor resection and artificial joint replacement group (P = 0.986). The survival rates at 1, 3, and 5 years were 95%, 75%, and 45%, respectively, in the amputation group, 95%, 75%, and 35%, respectively, in the massive osteoarticular allograft group, and 92.3%, 78.8%, and 53.8%, respectively, in the tumor resection and artificial joint replacement group (P > 0.05).
CONCLUSIONS: The selection of the optimal surgical method for upper tibia osteosarcoma should be made according to the individual circumstances of the patient. Our study has significance for reducing the incidence of surgical complications and improving the quality of postoperative life.
© 2017 S. Karger GmbH, Freiburg.

Entities:  

Keywords:  Prognostic analysis; Surgical methods; Upper tibia osteosarcoma

Mesh:

Year:  2017        PMID: 28848134     DOI: 10.1159/000477251

Source DB:  PubMed          Journal:  Oncol Res Treat        ISSN: 2296-5270            Impact factor:   2.825


  7 in total

1.  Diosgenin inhibits the epithelial-mesenchymal transition initiation in osteosarcoma cells via the p38MAPK signaling pathway.

Authors:  Huaming Huang; Chao Nie; Xiaokang Qin; Jie Zhou; Lei Zhang
Journal:  Oncol Lett       Date:  2019-08-23       Impact factor: 2.967

2.  lncRNA LSINCT5 Regulates miR-20a-5p/XIAP to Inhibit the Growth and Metastasis of Osteosarcoma Cells.

Authors:  Shi-An Liao; Jian Guan; Hao Mo; Ju-Liang He; Xin-Li Zhan
Journal:  Onco Targets Ther       Date:  2020-08-18       Impact factor: 4.147

Review 3.  Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis.

Authors:  Evgenia Papakonstantinou; Alexandros Stamatopoulos; Dimitrios I Athanasiadis; Efstathios Kenanidis; Michael Potoupnis; Anna-Bettina Haidich; Eleftherios Tsiridis
Journal:  J Bone Oncol       Date:  2020-09-15       Impact factor: 4.072

4.  LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis.

Authors:  Dong Fu; Chunwen Lu; Xingzhou Qu; Peng Li; Kai Chen; Liancheng Shan; Xiaodong Zhu
Journal:  Aging (Albany NY)       Date:  2019-10-10       Impact factor: 5.682

5.  LINC00467 facilitates osteosarcoma progression by sponging miR‑217 to regulate KPNA4 expression.

Authors:  Jing Yan; Tao Fang; Ming Zhang; Quan Zhou
Journal:  Int J Mol Med       Date:  2021-02-04       Impact factor: 4.101

6.  Clinical Application of Artificial Intelligence: Auto-Discerning the Effectiveness of Lidocaine Concentration Levels in Osteosarcoma Femoral Tumor Segment Resection.

Authors:  Shuqin Ni; Xin Li; Xiuna Yi
Journal:  J Healthc Eng       Date:  2022-03-28       Impact factor: 2.682

7.  Elevated Expression of miR-629 Predicts a Poor Prognosis and Promotes Cell Proliferation, Migration, and Invasion of Osteosarcoma.

Authors:  Xuesen Li; Na Li; Qinghui Niu; Haibin Zhu; Zhijie Wang; Qingxian Hou
Journal:  Onco Targets Ther       Date:  2020-03-02       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.